Preclinical Services | In Vitro Services

We have extensive experience with over 200 human and non-human cell lines including the NCI-60 panel evaluating drug activity and selectivity using quantitative cell-based assays measuring cell viability, proliferation, drug uptake, and biomarker expression and activation including:

  • Lead candidate identification and optimization
  • IC50 determinations
  • Combination and sequence dosing and analysis
  • Effects of agents on cell cycle and apoptosis
  • Enzyme and receptor binding assays
  • Signal transduction and mechanism of action studies

 

Contact

Theresa A. Mays

Michael J. Wick, Ph.D.
Director, Preclinical Research
Phone: (210) 593-5296
Fax: (210) 593-5297
E-mail: michael.wick@startsa.com